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It has been reported that hepatocellular carcinoma (HCC) is the most common primary 
malignancy of the liver [1], representing the second leading cause of cancer-related deaths 
worldwide [2], its hypervascular nature underlines the importance of angiogenesis in the 
pathophysiology of this tumour [3]. Amongst its clinical management, the main non-surgical 
method is image-guided percutaneous radiofrequency ablation (RFA), which causes tumour 
necrosis through inducing high intra-tumoral temperatures [1]. We read the manuscript entitled 
“Angiogenesis in residual cancer and roles of HIF-1α, VEGF, and MMP-9 in the development of 
residual cancer after radiofrequency ablation and surgical resection in rabbits with liver cancer” by 
Li et al with great interest. [4]. The authors investigated the blood flow signal changes in residual 
cancer after ultrasound-guided RFA of rabbit liver cancer, and analysed the correlation between 
changes in blood flow signal and changes in Hypoxia-inducible factor 1-alpha (HIF-1α), vascular 
endothelial growth factor (VEGF), and matrix metallopeptidase 9 (MMP-9). Additionally, the 
potential link between blood flow signals and angiogenesis in residual cancer, after RFA and 
surgical resections in rabbits with liver cancer was investigated [4]. Tissue fragments were collected 
from each rabbit and included in the control, RFA, and surgical resection groups, which were 
subsequently stained and used to determine the microvascular density (MVD). They found that the 
blood flow signal was positively correlated with the VEGF expression, MMP-9 expression, and the 
MVD in both the RFA and surgical resection groups. In particular, the higher the blood flow signal 
grade, the higher the VEGF and MMP-9 expression and MVD. At later time points (days 7 and 14), 
the VEGF expression, MMP-9 expression and the MVD, were found to be higher in RFA samples 
than in surgical resection samples. These findings have led the authors to conclude that in the 
control, RFA, and surgical resection groups, the ultrasound blood flow signal is associated with the 
expression of the two angiogenesis-related factors, VEGF and MMP-9, and the MVD [4].  
As reported by the authors, micro-angiogenesis was assessed according to the MVD staining 
method proposed by Wendy. In particular, a) brownish yellow staining of the interstitial substance 
indicated positive cells; b) cell masses near the positive staining were attributed as vessels, and c) 
vessels were counted under low magnification in three selected fields with a relatively dense 
distribution. The expression of VEGF and MMP-9 in liver cancer was, instead, measured using the 
S-P method. In the present manuscript however, the authors do not mention important 
methodological details or useful references (for example explaining the meaning of “MVD staining 
method proposed by Wendy” or “VEGF and MMP-9 in liver cancer was measured using the S-P 
method”) limiting the reproducibility of their findings. Furthermore, general observations need to 
be discussed with the aim of enhancing the scientific value of the study. In particular, it has been 
demonstrated that angiogenesis is regulated by a dynamic balance of pro- and anti-angiogenic 
factors secreted from cancer cells, endothelial cells and stromal cells [5]. It is also ascertained that 
angiogenic vessels have a “disorganized” and “irregular” structure, and that the blood flow is 
abnormal and characterized by a non-linear behaviour [6, 7]. Sprouting angiogenesis, one of the 
seven distinct ways (i.e. vasculogenesis, intussusceptive angiogenesis, vascular co-option, mosaic 
vessels, vasculogenic mimicry and trans-differentiation of cancer stem-like cells into tumour 
endothelial cells) in which malignant tumours can generate their vasculature, can be represented as 
a dynamic process that is discontinuous in space and time, but advances through differnet 
consecutive “states”. In geometrical terms, the continuous generation of these states determines a 
complex ramified structure that irregularly fills the surrounding environment. The main feature of 
the newly generated vasculature is the multifarious diversity of the vessel sizes, shapes, and 
connecting patterns. Despite its potential importance as a prognostic indicator in untreated tumours, 
MVD has not yet been revealed to be an appropriate measure for determining local micro-
angiogenesis [8]. MVD does not appear to be predictive of tumour response under anti-angiogenic 
treatment and therefore may not be useful for stratifying patients for clinical trials [8]. Low MVD 
does not portend a poor response to anti-angiogenic therapy and tumour MVD may not vary in 
accordance with the tissue or blood levels of any single pro-angiogenic factor. Moreover, rapid 
growth does not imply high MVD [8]. The MVD of a tumour need not be higher, and is often 
lower, than that of its corresponding natural counterpart, which is experiencing no net growth [9]. 
The efficacy of anti-angiogenic agents cannot be simply visualized by alterations in MVD during 
treatment. In addition, the MVD is substantially limited by the complex biology characterizing 
tumour vasculature [10] and the highly irregular geometry that the vascular system assumes in “real 
space” which cannot be measured (i.e. MVD is an estimate not a measure) using the principles of 
Euclidean geometry because it is only capable of interpreting regular and smooth objects that are 
almost impossible to find in nature [7]. Despite this, the authors have stated that: “MVD is a 
relatively accurate indicator for determining local microangiogenesis” and that “It is commonly 
used for local detection of tumours to determine the nature and recurrence of tumours”. It remains 
indubitable that scientific knowledge develops through the introduction of new concepts, and this 
process is usually driven by new and more appropriate methodologies that provide previously 
unavailable observations. It is without a doubt that the broad applicability of “quantitative methods” 
and not mere subjective qualitative or semi-quantitative indexes, makes it possible to explore the 
range of the morphological variability of neo-vasculature that can be produced in nature, thus 
increasing its importance in pre-clinical as well as clinical cancer research. 
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